货号:A128948
同义名:
CFTR Inhibitor II; Cystic Fibrosis Transmembrane Conductance Regulator Inhibitor II
GlyH-101是一种甘氨基氮化合物,是一种可逆的电压依赖性CFTR氯离子通道阻滞剂,Ki为4.3 μM。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | CFTR ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ataluren | ✔ | 98% | |||||||||||||||||
| Lumacaftor |
++++
F508del-CFTR, EC50: 0.1 μM |
98% | |||||||||||||||||
| CFTR(inh)-172 |
+++
CFTR, Ki: 300 nM |
99%+ | |||||||||||||||||
| GlyH-101 |
+
CFTR, Ki: 4.3 μM |
99%+ | |||||||||||||||||
| IOWH-032 |
++
CFTR, IC50: 1.01 μM |
99%+ | |||||||||||||||||
| Tezacaftor | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-activated epithelial Cl- channel. GlyH-101 is a glycine hydrazide compound that inhibits CFTR with a Ki value of 4.3±0.9μM. The inhibitory potency of GlyH-101 against CFTR was reduced at more negative voltages, with Ki values of 1.4, 3.8, 5.0, and 5.6μM for voltages of +60, +20, −20, and −60mV, respectively.[3] GlyH-101 inhibited cAMP/PKA-activated Cl- current in a dose- and voltage-dependent manner with IC50 values of 0.3±1.5 and 5.1±1.3μM at +100 and −100mV, respectively.[4] GlyH-101 at a dosage of 10μM rapidly and reversibly inhibited forskolin-induced hyperpolarization in nasal potential differences in mice (CD1 strain).[3] |
| 作用机制 | The inhibition of CFTR by GlyH-101 involves direct CFTR pore occlusion at a site at or near the extracellular-facing pore surface.[3] |
| Concentration | Treated Time | Description | References | |
| Rat pancreatic explants | 10 μmol/l | 1-7 days | GlyH-101 increased the absolute number of NGN3+ endocrine progenitors and the number of beta cells, as well as the expression of insulin and Mafa. | Diabetologia. 2013 Feb;56(2):330-9. |
| Murine renal proximal convoluted tubule cells (PCT) | 10 µM | GlyH-101 blocked more than 70% of the CaCC conductance at 10 µM. | Br J Pharmacol. 2014 Aug;171(15):3716-27. | |
| PS120 cells (non-CFTR expressing) | 0.5, 1, 5, 10 µM | GlyH-101 significantly inhibited VSORC currents with IC50 values of approximately 5.38 µM (negative potentials) and 6.26 µM (positive potentials). | Br J Pharmacol. 2014 Aug;171(15):3716-27. | |
| Murine renal distal convoluted tubule cells (DCT) | 0.5, 1, 5, 10 µM | GlyH-101 induced a concentration-dependent inhibition of the CFTR-like current, with almost complete inhibition at 10 µM and a more pronounced effect at positive potentials. | Br J Pharmacol. 2014 Aug;171(15):3716-27. | |
| Mouse beta-cells | 50 μM | 10 minutes | To investigate the effect of GlyH-101 on cAMP-enhanced insulin secretion, results showed that GlyH-101 significantly inhibited cAMP-enhanced insulin secretion. | BMC Med. 2014 May 28;12:87. |
| Human beta-cells | 50 μM | 10 minutes | To investigate the effect of GlyH-101 on cAMP-enhanced insulin secretion, results showed that GlyH-101 significantly inhibited cAMP-enhanced insulin secretion. | BMC Med. 2014 May 28;12:87. |
| Calu-3KD cells | 50 μM | 30 minutes | GlyH-101 partially inhibited CFTR channel activity in Calu-3KD cells, but responses to lubiprostone and CCh were retained. | Br J Pharmacol. 2007 Apr;150(8):1055-65. |
| Calu-3WT cells | 50 μM | 30 minutes | GlyH-101 completely inhibited CFTR channel activity in Calu-3WT cells, resulting in no response to lubiprostone or CCh. | Br J Pharmacol. 2007 Apr;150(8):1055-65. |
| Human airway smooth-muscle cells | 2 μM | 5 hours | To evaluate the effects of GlyH-101 on cellular sphingolipid composition. Results showed GlyH-101 increased sphinganine and dihydroceramides. | Am J Respir Cell Mol Biol. 2020 Nov;63(5):690-698. |
| Human alveolar epithelial cell line A549 | 2 μM | 5 hours | To evaluate the effects of GlyH-101 on cellular sphingolipid composition. Results showed GlyH-101 increased sphinganine and dihydroceramides. | Am J Respir Cell Mol Biol. 2020 Nov;63(5):690-698. |
| Calu-3 cells | 10 μM | GlyH-101 had no effect on the mean alkalinization produced by the removal of basolateral Cl- under non-stimulated conditions, but in the presence of GlyH-101, the cAMP agonist forskolin failed to fully inhibit the basolateral exchanger | Br J Pharmacol. 2013 Apr;168(8):1946-60. | |
| Normal Human Bronchial Epithelial cells (NHBE) | 10 μM | 20-50 minutes | GlyH-101 significantly blocked H2O2-induced CFTR-dependent current changes | Am J Respir Cell Mol Biol. 2013 Oct;49(4):672-9. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Pregnant E12.5 mice | Subcutaneous injection | 10 mg/kg | Twice daily for six consecutive days | GlyH-101 increased the surface area of insulin+ and glucagon+ cells in E18.5 pancreases but did not modify beta cell proliferation. | Diabetologia. 2013 Feb;56(2):330-9. |
| Mice | SPT-deficient mice | Intratracheal administration | 80 mg/kg | Single dose, evaluated after 4 hours | To evaluate the effects of GlyH-101 on airway hyperreactivity. Results showed GlyH-101 decreased AHR in SPT-deficient mice. | Am J Respir Cell Mol Biol. 2020 Nov;63(5):690-698. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.03mL 0.41mL 0.20mL |
10.14mL 2.03mL 1.01mL |
20.28mL 4.06mL 2.03mL |
|
| CAS号 | 328541-79-3 |
| 分子式 | C19H15Br2N3O3 |
| 分子量 | 493.15 |
| SMILES Code | O=C(N/N=C/C1=CC(Br)=C(O)C(Br)=C1O)CNC2=CC=C3C=CC=CC3=C2 |
| MDL No. | MFCD01532954 |
| 别名 | CFTR Inhibitor II; Cystic Fibrosis Transmembrane Conductance Regulator Inhibitor II |
| 运输 | 蓝冰 |
| InChI Key | RMBDLOATEPYBSI-NUGSKGIGSA-N |
| Pubchem ID | 135476586 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 55 mg/mL(111.53 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1